MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2023 International Congress

    The effect of cathodal transcranial direct current stimulation in the treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease: a preliminary report.

    B. Angeloni, R. Di Iorio, F. Bove, P. Sanginario, C. Piano, A R. Bentivoglio, P. Calabresi (Rome, Italy)

    Objective: Our study aims to demonstrate the possible effect of transcranial direct current stimulation (tDCS) in the treatment of Levodopa-induced dyskinesias (LIDs) in patients with…
  • 2023 International Congress

    Efficacy and safety of deutetrabenazine in children and adolescents with dyskinesia in cerebral palsy

    D. Claassen, L. Dure, H. Barkay, S. Barash, G. Yiu, L. Voisin, L. Marinelli, P. Moshkov, J-M. Savola, M. Chen, N. Chaijale, M. Gordon, A. Ahn (Nashville, USA)

    Objective: To evaluate the efficacy and safety of deutetrabenazine (DTBZ) in children and adolescents with dyskinesia in cerebral palsy (DCP). Background: There are currently no…
  • 2022 International Congress

    Evaluation of the effect of adding a mGlu2/3 orthosteric antagonist to a highly selective 5-HT2A antagonist on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine whether the therapeutic effect of serotonin 2A (5-HT2A) receptor antagonism on dyskinesia and psychosis may be reversed by orthosteric antagonism of metabotropic…
  • 2022 International Congress

    The mGlu2 positive allosteric modulator BINA extends enhances low dose L-DOPA anti-parkinsonian action in the MPTP-lesioned marmoset

    C. Kwan, I. Frouni, S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine the effect of positive allosteric modulation of the metabotropic glutamate type 2 (mGlu2) receptor in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset using a low…
  • 2022 International Congress

    Fingolimod-responsive complex hyperkinetic movement disorder in neuromyelitis optica spectrum disorder

    RE. Cortes, JA. Vatanagul, G. Saranza (Cebu, Philippines)

    Objective: Highlight a complex hyperkinetic movement disorder in Neuromyelitis optica spectrum disorder exacerbation with remission on fingolimod therapy. Background: Neuromyelitis optica spectrum disorder (NMOSD) can…
  • 2022 International Congress

    Elimination of STN stimulation-induced dyskinesias with ViM DBS

    D. Shah-Zamora, J. Karl, L. Verhagen (Chicago, USA)

    Objective: To describe effects of thalamic deep brain stimulation (DBS) on severe dyskinesias induced by subthalamic nucleus (STN) DBS in a person with Parkinson’s disease…
  • 2022 International Congress

    Cognitive and Motor aspects of a Brazilian population with Parkinson´s disease and Impulse Control Disorders and/or Related Behaviors – an observational study.

    B. Veiga, C. da Silva, L. Barcelos, H. Ferraz, S. Silva, V. Borges (São Paulo, Brazil)

    Objective: We analysed if Impulse Control Disorders (ICDs) and/or Related Behaviors (RBs) were associated with levodopa-induced dyskinesia (LIDs) in Brazilian patients with Parkinson´s disease (PD)…
  • 2022 International Congress

    Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson’s disease

    M. Dileone, C. Ammann, V. Catanzaro, C. Pagge, R. Piredda, MHG. Monje, I. Navalpotro-Gómez, A. Bergareche, MC. Rodriguez-Oroz, L. Vela, F. Alonso-Frech, MJ. Catalán-Alonso, JA. Molina, N. López-Ariztegui, A. Oliviero, JA. Obeso, G. Foffani (Móstoles, Spain)

    Objective: To investigate the potential of transcranial static magnetic field stimulation (tSMS) as a non-pharmacological, non-invasive, home-based treatment to manage levodopa-induced dyskinesias (LIDs) in Parkinson’s…
  • 2022 International Congress

    Bitopertin, a GlyT1 inhibitor, attenuates the development of dyskinesia in the 6-OHDA-lesioned rat

    I. Frouni, W. Kang, D. Bédard, S. Belliveau, C. Kwan, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin at preventing dyskinesia development in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s…
  • 2022 International Congress

    Relationship between lesion topography and incidence of dyskinesias following focused ultrasound subthalamotomy.

    J. Máñez-Miró, R. Rodríguez-Rojas, J. Pineda-Pardo, M. Del álamo, R. Martinez-Fernandez, J. Obeso (Mostoles, Spain)

    Objective: To describe the relation between the topography of subthalamotomy by focused ultrasound (FUS) for the treatment of Parkinson’s disease (PD) (1), and the risk…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 49
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley